TY  - JOUR

T1  - Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA)  RADAR trial in newly diagnosed transplant eligible patients

JO  - Blood

UR  - https://doi.org/10.1182/blood-2025-98

PY  - 2025/11/03

AU  - Ramasamy K

AU  - Royle K-L

AU  - Cicero R

AU  - de Tute R

AU  - Jenner M

AU  - Bygrave C

AU  - Popat R

AU  - Mehta D

AU  - Chiecchio L

AU  - Balik B

AU  - Kazeroun M et al

ED  - 

DO  - DOI: 10.1182/blood-2025-98

PB  - American Society of Hematology

VL  - 146

IS  - Supplement 1

SP  - 98

EP  - 98

Y2  - 2026/07/16

ER  -